Fennec Pharmaceuticals Announces Over the Counter Trading Symbol Change

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Sept. 5, 2014) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:ADHXD) (the "Company") formerly known as Adherex Technologies Inc., today announced that the Financial Industry Regulatory Authority ("FINRA") has approved the Company's corporate actions regarding its previously announced name change and share consolidation. As of open of business on September 5, 2014, the Company's OTC symbol will be ADHXD. The "D" has been appended as the 5th character for 20 business days. After 20 business days, the Company's OTC ticker symbol will change to "FENCF".

About the Company

The Company is a biopharmaceutical company focused on cancer therapeutics. The Company's principal executive offices are located at PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, NC. The Company's telephone number is [phone].

Forward-Looking Statements

Except for historical information described in this press release, all other statements are forward-looking. In particular, this press release contains, without limitation, forward-looking statements pertaining to the expected date upon which the post-Consolidation Common Shares and listed warrants will begin trading on the Toronto Stock Exchange. With respect to forward-looking statements contained in this press release, we have made assumptions regarding various matters. Although we believe that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, we cannot assure you that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this press release, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, the risks described in the Offer Letter and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2013. Fennec Pharmaceuticals Inc. disclaims any obligation to update these forward-looking statements except as required by law.

For a more detailed discussion of related risk factors, please refer to the Company's public filings available at www.sec.gov and www.sedar.com.

Fennec Pharmaceuticals Inc.
Rosty Raykov
Chief Executive Officer
[phone]